|
|
8624 154th Avenue NE
Redmond, WA 98052 USA
phone:425-869-2100
fax:425-882-2137
|
|
| Symbol |
Private |
| Founded |
2001 |
| Employees |
|
|
|
| www.archususa.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. |
|
| Management |
| Jim Fitzsimmons, Chairman and CEO; Thomas J. McLeer, Vice President, Sales and Marketing; Teena M. Augostino, Vice President, Regulatory & Clinical Affairs; Robert W. Calcote, Vice President, Operations; Joe Basista, Vice President of Intellectual Property; Leonard J. Tokish, Jr.- Vice President, R & D; Mark Landis - Director of Finance & Administration |
| |
|
|
| |
|
| Keywords |
| Degenerative disease, Total Facet Arthroplasty System, TFAS, Archus Bone Cement, Polymethylmethacrylate, PMMA |
|
|
|
| Description |
|
Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. Archus Orthopedics, Inc. began U.S. clinical trials of its Total Facet Arthroplasty System (TFAS) in August 2005. The TFAS is a novel, patented spinal implant designed to treat spinal stenosis, a condition in which degenerative changes in the facet joints result in compression of spinal nerves producing neurological symptoms in the legs. Traditionally, patients with spinal stenosis undergo decompressive laminectomy surgery, which is often accompanied by spinal fusion. The TFAS replaces the degenerative facet joints with a prosthetic joint implant intended to restore stability and normal motion to the spine, eliminating the need for fusion. |
|
| Products / Services |
The company's product offerings include the TFAS, an articulating joint prosthesis intended to restore normal motion and to provide stabilization of spinal segments in skeletally mature patients. TFAS is offered in a range of sizes to address the specific anatomical requirements of each patient.
|
|
| Technology / Differentiation |
| TFAS is comprised of implantable grade metal components fixed within the pedicles, providing immediate alignment and stabilization while maintaining anatomical ranges of motion. Archus Bone Cement, containing 30% barium sulfate, is the only cement validated for use as a component of the TFAS system. |
|
| Market / Customers |
The worldwide spine market is valued at over $5 billion and growing at a rate greater than 20 percent annually. Chronic back pain is the largest cause for missed work and among the most frequent reason patients visit physicians. More than 50 percent of patients with chronic back pain exhibit some or most pain in the facet joints.
|
|
| Status |
| Patients are currently being enrolled and treated at Phase One investigative sites. Archus Orthopedics is currently recruiting clinical investigators for Phase Two of the trial. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members